James F Marion, MD
- PROFESSOR | Medicine, Gastroenterology
- Celiac Disease
- Colon Polypectomy
- Colon Polyps
- Crohn's Disease
- Inflammatory Bowel Disease
- Ulcerative Colitis
MD, Columbia Univ. Col. of Phy. & Surg.
Residency, Internal Medicine, Columbia-Presbyterian Medical Ctr.
Residency, Internal Medicine, Columbia-Presbyterian Medical Center
Fellowship, Gastroenterology, Mount Sinai Hospital
- A Double-Blind Randomized Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
This is a Phase 3 double-blind randomized multicenter study of higher versus standard adalimumab dosing regimens for induction and maintenance therapy in subjects with moderately to severely active UC. This study will include a 3-Week Screening Period; an 8-Week Double-Blind I...
- A Phase 2, randomized, placebo-controlled, multicenter study to investigate the efficacy and safety of GED-0507-34-Levo (GED0507) for treatment of subjects with active ulcerative colitis
The purpose of this study is to test an investigational drug called GED0507. Investigational means it is still being studied to find out if it is safe and effective, what a safe dose is, and what the side effects are. The drug being tested in this study has not yet been approv...
- An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy with Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects with Crohn's Disease Stratified at Higher Risk for Developing Complications
The purpose of this study is to determine the effect of triple combination therapy with an anti-integrin (vedolizumab IV), a tumor necrosis factor (TNF) antagonist (adalimumab SC), and an immunomodulator (oral methotrexate) on endoscopic remission at Week 26.
- Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn's Disease. [MLN-0002_401]
Entyvio PASS is a long-term safety observational study to look at the safety and efficacy of vedolizumab compared to other biologic agents in treating Inflammatory Bowel Disease (IBD) such as Crohn's Disease (CD) and Ulcerative Colitis (UC). Vedolizumab was approved by the FDA...
- A Multicenter Randomized Double-Blind Study to Evaluate the Efficacy and Safety of Two Adalimumab Induction Regiments in Subjects with Moderately Severely Active Crohn's Disease and Evidence of Mucosal Ulceration
This is a randomized double-blind multicenter study of two adalimumab induction regimens in subjects with moderately to severely active Crohn's Disease (CD) with evidence of mucosal ulceration confirmed by central reading. No placebo arm is planned since there is well-document...
- A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn's Disease
This is a 40-week open-label extension study designed to evaluate the long-term efficacy, safety, and tolerability of adalimumab.
The purpose of this study is to evaluate the long-term efficacy, safety and tolerability of repeated subcutaneous (under the skin injecti...
- A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis (A3921139)
The purpose of this research study is to assess the safety and tolerability of long-term tofacitinib therapy in patients with Ulcerative Colitis (UC). A3921139 is an open label study, which means that tofacitinib (also known as tofacitinib citrate or CP-690,550) is given to al...